Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$12.6B
532M shares
52-week range
$20.02 – $27.64
49% from low
Exchange
NYSE
ADRC
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
www.freseniusmedicalcare.comNo one on the platform currently holds FMS.
No tracked institution reports a position in FMS as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-22 | $0.8643 | 2026-06-08 |
| 2025-05-23 | $0.8150 | 2025-06-06 |
| 2024-05-17 | $0.6428 | 2024-06-03 |
| Execution date | Ratio |
|---|---|
| 2012-12-04 | 2-for-1 |
No one on the platform has traded FMS yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $19.6B | +0.1% | $2.05 | $1.94–$2.21 | 11.6× | 3 |
| 2027 | $20.2B | +3.3% | $2.16 | $2.05–$2.36 | 11.0× | 5 |
| 2028 | $21.0B | +4.0% | $2.47 | $2.41–$2.62 | 9.6× | 2 |
| 2029 | $21.8B | +3.9% | $3.05 | $2.97–$3.23 | 7.8× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-03 | $0.62 | $0.66 | +7.1% |
| 2026-05-05 | $0.59 | $0.53 | -10.2% |
| 2026-02-24 | $0.65 | $0.83 | +28.3% |
| 2025-11-04 | $0.59 | $0.64 | +8.5% |
| 2025-08-05 | $0.50 | $0.52 | +4.0% |
| 2025-05-06 | $0.43 | $0.44 | +2.3% |
| 2025-02-25 | $0.41 | $0.48 | +17.1% |
| 2024-11-05 | $0.38 |
| $0.45 |
| +18.4% |
| $12.8B |
| — |
| RPRXRoyalty Pharma plc | $58.56 | -1.11% | $26.0B | — |
| SNNSmith & Nephew plc | $30.11 | +0.90% | $12.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
$ICU Malaria is still bizarrely prevalent in the third world. The SCD-PED will be made available to its children at a greatly reduced cost. JMHO.. Perhaps both $FMS & $BAX will follow suit with their dialysis units. God Bless the Children. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(26)00146-4/fulltext
View on StockTwits ↗@BULLISH1975 $FMS- USA $BAX (Vantive)- International? The CMO and Dr. Goldstein (co-inventor) did have Baxter badges on two+ years ago in San Diego@ the Kidney conference and their dialysis prismaflex devices were featured in this week’s SeaStar YouTube presentation!
View on StockTwits ↗DaVita’s $DVA Vafseo $AKBA rollout : • 100+ clinic pilot began 8/18/25 • Went “village-wide” on 11/10/25 • Pilot to village-wide access: 84 days Why this matters for $CRMD: • Similar timing could put DefenCath village-wide before potential MA contracts begin in early 2027 • That is a strong setup for $FMS -like adoption *Not a direct adoption comparison. Vafseo faced adherence issues, protocol changes, anemia-manager concerns, and decades of ESA inertia. Access did not equal immediate utilization.
View on StockTwits ↗@SparkyReturns @BeefStewart SAVE Registry termination and the CMS billing codes due Oct. 1 for the Pediatric device will be the first nut that cracks open. The second nut will be PMA to replace the HDE from the FDA. International partnerships for the Pediatric Device will then be arriving. When those agreements come to fruition…..kabang. International medical authorities will treat adults using the pediatric device until the larger unit becomes available. Just my thoughts. The cash burn will be completely irrelevant when the ball rolls overseas, up north and down south. ATMs and Lincoln or other megabuck investment houses will rally round SeaStar gliding us till March when the Neutralize-AKI study completes and $FMS grabs the production, sales, training and distribution ball here in the USA. If they pass Vantive, $BAX will be all over it. Internationally, I believe that Vantive will take the reins and make medical history with $FMS &$ICU. The DARPA burn sepsis grant=huge.
View on StockTwits ↗$AKBA $DVA $CRMD $FMS Amazing how the Davita CMO can impact patient care! (Forbes this week) https://www.forbes.com/councils/forbesbusinesscouncil/2026/08/12/leaving-the-bedside-doesnt-mean-leaving-patients-behind/
View on StockTwits ↗$AKBA $DVA $CRMD $FMS Davita is amazing company that truly cares about savings patients from preventable CBRSI infections! *2nd leading cause of mortality in dialysis Pilot starts Q3 😁 https://www.globenewswire.com/news-release/2026/08/13/3344407/0/en/cormedix-therapeutics-reports-second-quarter-2026-financial-results-and-provides-business-update.html
View on StockTwits ↗@local42r @MasheredTrader If: $FMS, $BAX (Vantive), do partner up, $FMS in the USA while Vantive handles the international marketplace, then a 10M share float is very possible, 15M max….agreed. Both companies have massive organizations in place, worldwide. DaVita is located right in Denver with SeaStar. They’re a long running, successful dialysis provider and may have Schlorff’s ear, as well. A myriad of possibilities which will spread this Nobel prize winning medical science into every major hospital and 20-50% of every minor hospital worldwide. The Holiest of Grails is right here. A solid ER today with some great financial and sales forecasts, with particulars and details about who, what, when, how soon, and then what, why, obviously, apparently and of course!
View on StockTwits ↗$IOVA $ICU Medtronic supplies $FMS with SCD components for the device’s assembly. Don’t be surprised if they aren’t part of SeaStar’s international sales, training and distribution conglomerate soon to hatch. DYOR. NFA. https://www.medicaldevice-network.com/news/medtronic-ablation-system-lands-ventricular-arrhythmia-indication-expansion-in-europe/
View on StockTwits ↗@Yoda896 been hearing this song about $CRMD for 7-8 yrs. Wall st has 0 trust in the leadership team and they have some good reason. We can't say Defencath was a success until we see what they can do now they're off the nipple. There's once again a whole bunch of risk in this... Elliot managment got the $FMS deal done, not Joe T... That's why they sold all their shares as soon the deal was inked.
View on StockTwits ↗$CRMD $FMS FMC Q2 earrings call “we are beginning to see the impact of our catheter-related bloodstream infection prevention efforts. We saw a 23% reduction in bloodstream infections over the past year, which supports lower infection-related hospitalizations and also translates into lower patient mortality risk.” https://freseniusmedicalcare.com/content/dam/fresenius-medical-care/global/en/03_investors/pdf/03_publications/2026/q2/Q2_2026_Earnings-call-transcript_Nasdaq.pdf
View on StockTwits ↗$CRMD $FMS $DVA Q2 Earnings Season Started to show the first signs of Defencath impact between the two LDOs Davita missed Treatment worsen versus it’s own Plan/ Internal Forecasts While Fresenius Reported favourable improvement on missed Treatment and mortality The Trend will likely expand exponentially
View on StockTwits ↗Wall St is expecting 0.62 EPS for $FMS Q3 [Reporting 11/03 BMO] http://www.estimize.com/intro/fms?chart=historical&metric_name=eps&utm_cont
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.